黑色素瘤相关抗原A10对非肌层浸润性膀胱癌术后复发的评估价值

Abstract
Figure/Table
References (25)
Related Citation (14)

Download: PDF (785 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the estimated value of melanoma-associated antigen A10 (MAGE-A10) in the postoperative recurrence of patients with non-muscular invasive bladder cancer (NMIBC) after transurethral resection of bladder tumor (TURBt). Methods The age, gender, MAGE-A10 positive expression, tumor size, tumor grade, tumor stage, with or wthout immediate bladder perfusion, with or wthout postoperative tumor recurrence, and recurrence time of 106 patients with NMIBC from March 2016 to June 2020 in Suqian Hospital Affiliated to Xuzhou Medical University were retrospectively analyzed, the independent risk factors for postoperative recurrence were analyzed. Results Among 106 patients, 41 patients (38.68%) were MAGE-A10 positive. The patients were followed up for 12~51 months after operation, of which 46 cases (43.40%) recurred. The number of MAGE-A10 positive, tumor number, tumor size, tumor grade, and tumor stage had significant influence on postoperative tumor recurrence (P ＜ 0.01). Cox univariate and multivariate regression analysis were found that MAGE-A10 positive, high tumor grade, and high tumor stage were independent risk factors for postoperative tumor recurrence (P ＜ 0.05). There was significant difference in the median recurrence free survival time between MAGE-A10 positive and negative groups (P ＜ 0.01). The area under the curve of receiver operator characteristic curve for predicting postoperative recurrence of patients with MAGE-A10 was 0.773 (P ＜ 0.05). Conclusion The positive expression of MAGE-A10 is a related risk factor for the recurrence of the patients of non-muscular invasive bladder cancer, and it might be considered as a new potential indicator for evaluating the recurrence of the patients of non-muscular invasive bladder cancer.

Key words： Bladder cancer Melanoma associated antigen A10 Tumor recurrence Cox regression analysis Receiver operator characteristic curve

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Xiangyu1 CAI Longjun1 SHI Long1 CAI Weiqi1 ZHANG Jianjun2▲

Cite this article:

WANG Xiangyu1 CAI Longjun1 SHI Long1 CAI Weiqi1 ZHANG Jianjun2▲. The estimated value of melanoma-associated antigen A10 for the postoperative recurrence of non-muscular invasive bladder cancer[J]. 中国医药导报, 2022, 19(17): 135-138.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2022/V19/I17/135

[1] Zhang JJ，Cai LJ，Pang K，et al. Paeonol inhibits proliferation and induces cell apoptosis of human T24 and 5637 bladder cancer cells in vitro and in vivo [J]. Clin Trans Oncol，2021，23（3）：601-611.
[2] 曹达龙，叶定伟.免疫治疗在膀胱癌中的最新研究进展和未来展望[J].中国癌症杂志，2018，28（2）：81-87.
[3] 王英，杨树林，张秉鸿，等.不同尿流改道术式对膀胱癌全膀胱切除术相关指标、术后并发症及预后的影响[J].实用医院临床杂志，2021，18（3）：93-96.
[4] Shore ND，Palou Redorta J，Robert G，et al. Non-muscle-invasive bladder cancer：An overview of potential new treatment options [J]. Uro Oncol，2021，39（10）：642-663.
[5] 李彦泽，王磊，陈志远，等.晚期膀胱癌PD-1/PD-L1抑制剂治疗的研究进展[J].中国医药导报，2020，17（4）：40-43.
[6] Yassaie O，Chehroudi C，Black PC. Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma [Z]. England：SAGE Publications，2021，13：17516212.
[7] Dong Y，Ma W，Shi Z，et al. Role of NRP1 in Bladder Cancer Pathogenesis and Progression [J]. Frontiers in Oncology，2021，11：685980.
[8] Dobruch J，Oszczud?覥owski M. Bladder Cancer：Current Challenges and Future Directions [J]. Medicina，2021，57（8）：749.
[9] 张建军，蔡龙俊，晁流，等.黑色素瘤相关抗原Ａ10和树突状细胞在非肌层浸润膀胱癌中的表达及其意义[J].临床医药实践，2020，29（10）：732-735.
[10] Mengus C，Schultz-Thater E，Coulot J，et al. MAGE-A10 cancer/testis antigen is highly expressed in high-grade non-muscle-invasive bladder carcinomas [J]. Int J Cancer，2013，132（10）：2459-2463.
[11] 刘安，张建斌.即刻灌注吉西他滨对非肌层浸润性膀胱癌术后预后的影响[J].解放军医药杂志，2018，30（10）：31-33.
[12] Slovacek H，Zhuo J，Taylor JM. Approaches to Non-Muscle-Invasive Bladder Cancer [J]. Curr Oncol Rep，2021， 23（9）：105.
[13] Siegel R，Miller K，Jemal A. Cancer Statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
[14] 赵家红，张伟，李佳伟，等.非肌层浸润性膀胱癌的危险分层工具和预后模型的研究进展[J].肿瘤防治研究，2020，47（4）：309-312.
[15] Kim LHC，Patel MI. Transurethral resection of bladder tumour（TURBT）[J]. TransAndrol Urol，2020，9（6）：3056-3072.
[16] 薛炜，邱建新，桑楠，等.影响非肌层浸润性膀胱癌患者经尿道膀胱肿瘤电切术后复发的相关因素分析[J].实用医院临床杂志，2019，16（5）：30-33.
[17] 黄健，刘皓.非肌层浸润性膀胱癌的诊治现状与对策[J].中华泌尿外科杂志，2019，40（7）：481-484.
[18] 曹志文，宋东奎，魏晓松，等.术前全身免疫炎症指数对非肌层浸润性膀胱癌患者肿瘤复发的预测价值[J].天津医药，2021，49（2）：159-164.
[19] 胡宏业，徐炜，吴宜龙，等.术前外周血中性粒细胞与淋巴细胞比值评估经尿道膀胱肿瘤电切术后非肌层浸润性膀胱癌患者预后的价值[J].广西医学，2019，41（12）：1499-1501.
[20] 张莲，陈松，张卫兵，等.高级别T1膀胱癌术后肿瘤复发与进展的相关影响因素[J].现代泌尿外科杂志，2019， 24（11）：938-943.
[21] López-Cortés R，Gómez BB，Vázquez-Estévez S，et al. Blood-based protein biomarkers in bladder urothelial tumors [J]. J Proteomics，2021，247：104329.
[22] Schultz-Thater E，Piscuoglio S，Iezzi G，et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung，skin and urothelial malignancies [J]. Int J Cancer，2011，129（5）：1137-1148.
[23] Kim J，Hwang IC. Drawing Guidelines for Receiver Operating Characteristic Curve in Preparation of Manuscrip-ts [J]. J Korean Med Sci，2020，35（24）：e171.
[24] 王彦光，朱鸿斌，徐维超.ROC曲线及其分析方法综述[J].广东工业大学学报，2021，38（1）：46-53.
[25] 张竹，许乐，贾文卓.基于ROC曲线分析血清miR375、miR106ｂ和AFP在肝癌早期诊断中的价值[J].标记免疫分析与临床，2020，27（5）：779-838.